Boston Scientific Corporation $BSX Shares Bought by Jennison Associates LLC

Jennison Associates LLC grew its position in shares of Boston Scientific Corporation (NYSE:BSX) by 10.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,468,295 shares of the medical equipment provider’s stock after acquiring an additional 529,549 shares during the quarter. Jennison Associates LLC’s holdings in Boston Scientific were worth $521,402,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FWL Investment Management LLC acquired a new stake in Boston Scientific during the second quarter worth about $26,000. Murphy & Mullick Capital Management Corp increased its stake in Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares during the last quarter. Financial Consulate Inc. acquired a new stake in Boston Scientific during the third quarter worth about $25,000. United Community Bank increased its stake in Boston Scientific by 115.7% during the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares during the last quarter. Finally, Colonial Trust Co SC increased its stake in Boston Scientific by 502.2% during the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 231 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Jefferies Financial Group dropped their price target on Boston Scientific from $110.00 to $100.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Needham & Company LLC lowered their target price on Boston Scientific from $97.00 to $77.00 and set a “buy” rating for the company in a research note on Thursday, April 23rd. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. UBS Group lowered their target price on Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a research note on Tuesday, March 17th. Finally, Raymond James Financial reiterated an “outperform” rating and issued a $88.00 target price (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $93.91.

Insider Buying and Selling

In related news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Price Performance

BSX stock opened at $56.52 on Thursday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. Boston Scientific Corporation has a 1 year low of $56.05 and a 1 year high of $109.50. The firm has a market cap of $84.00 billion, a P/E ratio of 23.61, a price-to-earnings-growth ratio of 1.10 and a beta of 0.78. The stock has a 50-day simple moving average of $67.42 and a 200-day simple moving average of $84.91.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.68% and a net margin of 17.29%.Boston Scientific’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities analysts predict that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: New clinical data reinforce long‑term growth opportunities in electrophysiology and stroke devices (FARAPULSE PFA, WATCHMAN). These trial results support BSX’s addressable market and product leadership — a positive fundamental counterweight to recent setbacks. Boston Scientific Trial Wins Highlight Growth Potential In Electrophysiology And Stroke Care
• Positive Sentiment: Large manager activity: Lone Pine (Stephen Mandel) reportedly opened a new position in BSX, which can signal conviction from a major investor and provide support to the stock over time. Boston Scientific Corporation (BSX): Stephen Mandel Opens New Position
• Neutral Sentiment: Media/TV commentary is mixed — Jim Cramer said “I think they can come back,” acknowledging competitive pressure but leaving a bullish recovery case on the table; this is sentiment‑driven and not an immediate catalyst. Jim Cramer on Boston Scientific: “I Think They Can Come Back”
• Neutral Sentiment: Health‑care sector weakness is also weighing on BSX alongside broader late‑session weakness in the group — a market‑level headwind rather than company‑specific news. Sector Update: Health Care Stocks Fall Late Afternoon
• Negative Sentiment: Multiple securities‑fraud class actions and law‑firm notices with a May 4 lead‑plaintiff deadline have been filed/announced, alleging misrepresentation of U.S. electrophysiology growth and sales trends. Legal risk and potential damages are pressuring sentiment and trading. BSX Investor Alert: Securities Fraud Lawsuit
• Negative Sentiment: Analyst downgrades and target cuts have piled up after guidance reduction and deal concerns; price targets have been trimmed and at least one shop moved BSX from strong‑buy to hold — analysts cutting estimates typically increases short‑term selling pressure. Boston Scientific (BSX) price target decreased by 11.24% to 90.30
• Negative Sentiment: Institutional trimming: Polen Focus Growth disclosed it sold its BSX stake citing competition concerns — another signal of investor caution. Polen Focus Growth Sold Its Stake in Boston Scientific (BSX)

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.